astrazeneca oral glp 1 AstraZeneca's obesity drug Elecoglipron has advanced to Phase III clinical trials after delivering promising Phase II results, with patients achieving up to 11.8% weight loss over 36 weeks. This milestone highlights AstraZeneca enters weight-loss market with

Antiapoptotic and antiautophagic effects of glial cell line-derived neurotrophic factor and hepatocyte growth factor after transient middle cerebral artery occlusion in rats

451486 (Academic Press, 2022)

It works by inhibiting melanin synthesis and has shown promise in treating melasma and other hyperpigmentation disorders

Psychopharmacology 232(3):501507 Guan M, Liu X, Guo L et al (2021) Improved Pre-attentive Processing With Occipital rTMS Treatment in Major Depressive Disorder Patients Revealed by MMN

GPX4 inactivation is another key driver

Protect against nerve injury potentially helpful in neuropathic pain syndromes like diabetic neuropathy